# Combined top 10 from each PICO category for nccp-lung-guideline-full_cleaned.json

## Population

1. (Population, score 14) e survival was longer
in the afatinib group (3.3 months, 95% CI 2.79–4.40)
than it was in the placebo group (1.1 months, 0.95–
1.68; HR 0.38, 95% CI 0.31–0.48; p<0.0001).
| A National Clinical
Patient population
Patients with non-s
NSCLC that had pro
during or after plati
based doublet chem
Patient population
Patients with advan
squamous-cell NSC
have disease progre
during or after first
chemotherapy.
Patient population
Patients with previo
treated, PD-L1-posi
advanced NSCLC.
The following sing
positive tumours:
Patient population
Patients with locally
or metastatic ALK-p
lung cancer who ha
one prior pl

2. (Population, score 14) months, 0.95–
1.68; HR 0.38, 95% CI 0.31–0.48; p<0.0001).
| A National Clinical
Patient population
Patients with non-s
NSCLC that had pro
during or after plati
based doublet chem
Patient population
Patients with advan
squamous-cell NSC
have disease progre
during or after first
chemotherapy.
Patient population
Patients with previo
treated, PD-L1-posi
advanced NSCLC.
The following sing
positive tumours:
Patient population
Patients with locally
or metastatic ALK-p
lung cancer who ha
one prior platinum-
regimen.
l Guid
n:
squam
ogress
tinum-
mothe
n:
nced
CLC wh
ession
t-line
n:
ously
itive,
gle ag
n:
y adv

3. (Population, score 14) and non-co
Population:
Intervention:
Comparison:
Outcome:
Clinical question 2.2.2
In patients with periphe
cancer?
- Percutaneous fine ne
- Guided bronchoscop
- Video assisted thora
Population:
Intervention:
Comparison:
Outcome:
Clinical question 2.2.3
In NSCLC patients with e
ablative techniques?
Population:
Intervention:
Comparison:
Outcome:
Clinical question 2.2.4
For patients with NSCLC
a role for imaging surve
Population:
Intervention:
Comparison:
Outcome:
deline | Diagnosis, staging and treatment of
nical Questions in PICO format
ancer (NSCLC) patients with mediastinal and hilar adenopathy what i

4. (Population, score 14) mical shift MRI, non-c
Population: Patients with lung cancer with metastati
masses
Intervention: Chemical shift MRI, non-contrast CT, PE
Comparison: -
Outcome: Detection of metastatic spread to indet
Clinical question 2.2.6
For patients with NSCLC which of the following tests is most accura
PET-CT?
Population: Patients with NSCLC with brain metasta
Intervention: MRI, CT, PET-CT
Comparison: -
Outcome: Detection of brain metastases
Clinical question 2.2.7
For patients with NSCLC which of the following tests is most accura
bone scan, CT, MRI, PET-CT?
Population: For patients with NSCLC with suspected
Inter

5. (Population, score 14) of the following tests is most accura
PET-CT?
Population: Patients with NSCLC with brain metasta
Intervention: MRI, CT, PET-CT
Comparison: -
Outcome: Detection of brain metastases
Clinical question 2.2.7
For patients with NSCLC which of the following tests is most accura
bone scan, CT, MRI, PET-CT?
Population: For patients with NSCLC with suspected
Intervention: Isotope bone scan, CT, MRI, PET-CT
Comparison: –
Outcome: Detection of bone metastases
Clinical question 2.2.8
In patients with limited-stage SCLC on diagnostic CT, does PET-CT ch
Population: Patients with limited-stage SCLC on diag
Intervention

6. (Patients, score 14) ties, or patient preference. Seven patients (35%) treated surgically had tumours that
were ipsilateral to their primary tumour, and eight (40%) had metachronous metastases. Five-year overall
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002).
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease
(

7. (Patients, score 14) tients (35%) treated surgically had tumours that
were ipsilateral to their primary tumour, and eight (40%) had metachronous metastases. Five-year overall
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002).
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease
(p=0.008). Survival of patients who un

8. (Patients, score 14) ur, and eight (40%) had metachronous metastases. Five-year overall
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002).
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease
(p=0.008). Survival of patients who underwent adrenalectomy for synchronous and metachronous adrenal
metastases was not signi

9. (Patients, score 14) ive-year overall
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002).
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease
(p=0.008). Survival of patients who underwent adrenalectomy for synchronous and metachronous adrenal
metastases was not significantly different (p=0.81). Surgical resection of

10. (Patients, score 14) was longer
in the afatinib group (3.3 months, 95% CI 2.79–4.40)
than it was in the placebo group (1.1 months, 0.95–
1.68; HR 0.38, 95% CI 0.31–0.48; p<0.0001).
| A National Clinical
Patient population
Patients with non-s
NSCLC that had pro
during or after plati
based doublet chem
Patient population
Patients with advan
squamous-cell NSC
have disease progre
during or after first
chemotherapy.
Patient population
Patients with previo
treated, PD-L1-posi
advanced NSCLC.
The following sing
positive tumours:
Patient population
Patients with locally
or metastatic ALK-p
lung cancer who ha
one prior platinum-
r

## Intervention

1. (Intervention, score 14) otherapy
Row 4: Kelly et al., 2008|Concurrent chemoradiation + consolidation chemotherapy ± maintenance chemotherapy Row 1: Recommendation 2.6.3.1|Grade
Row 2: Induction or consolidation chemotherapy are not routinely recommended for patients receiving concurrent radical chemoradiotherapy.|B Row 1: Intervention||Control|Relative effect (95% CI)|
Row 2: |||Overall Survival|PFS
Row 3: Erlotinib|vs.|Cytotoxic chemotherapy|HR 0.95 (0.75 to 1.22)|HR 0.30 (0.24 to 0.38)
Row 4: Gefitinib|vs.|Paclitaxel + carboplatin|HR 0.95 (0.77 to 1.18)|HR 0.39 (0.32 to 0.48)
Row 5: Afatinib|vs.|Cytotoxic chemotherapy|HR 0.93

2. (Therapy, score 13) LC NOS. (NCCN, V8 2017) A recent Cochrane review (Santos et al., 2015) aimed to assess the effectiveness and safety of different
cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIb
and IV) NSCLC. The study included 51 trials: non-platinum single-agent therapy versus non-platinum
combination therapy (seven trials) and non-platinum combination therapy versus platinum combination
therapy (44 trials). The reviews results were as follows:
Non-platinum single-agent versus non-platinum combination therapy
Low-quality evidence suggests that these treatments hav

3. (Therapy, score 13) e review (Santos et al., 2015) aimed to assess the effectiveness and safety of different
cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIb
and IV) NSCLC. The study included 51 trials: non-platinum single-agent therapy versus non-platinum
combination therapy (seven trials) and non-platinum combination therapy versus platinum combination
therapy (44 trials). The reviews results were as follows:
Non-platinum single-agent versus non-platinum combination therapy
Low-quality evidence suggests that these treatments have similar effects on overall survival (H

4. (Therapy, score 13) ffectiveness and safety of different
cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIb
and IV) NSCLC. The study included 51 trials: non-platinum single-agent therapy versus non-platinum
combination therapy (seven trials) and non-platinum combination therapy versus platinum combination
therapy (44 trials). The reviews results were as follows:
Non-platinum single-agent versus non-platinum combination therapy
Low-quality evidence suggests that these treatments have similar effects on overall survival (HR
0.92, 95% confidence interval (CI) 0.72 to 1.17; p

5. (Therapy, score 13) cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIb
and IV) NSCLC. The study included 51 trials: non-platinum single-agent therapy versus non-platinum
combination therapy (seven trials) and non-platinum combination therapy versus platinum combination
therapy (44 trials). The reviews results were as follows:
Non-platinum single-agent versus non-platinum combination therapy
Low-quality evidence suggests that these treatments have similar effects on overall survival (HR
0.92, 95% confidence interval (CI) 0.72 to 1.17; participants = 1062; five RCTs), one

6. (Therapy, score 12) The study included 51 trials: non-platinum single-agent therapy versus non-platinum
combination therapy (seven trials) and non-platinum combination therapy versus platinum combination
therapy (44 trials). The reviews results were as follows:
Non-platinum single-agent versus non-platinum combination therapy
Low-quality evidence suggests that these treatments have similar effects on overall survival (HR
0.92, 95% confidence interval (CI) 0.72 to 1.17; participants = 1062; five RCTs), one year OS (risk
ratio (RR) 0.88, 95% CI 0.73 to 1.07; participants = 992; four RCTs), and PFS (HR 0.94, 95% CI 0.83
to

7. (Therapy, score 12) latinum therapy plus pemetrexed (10.1 months vs.
Intervention:
progression after first-line 4.4 months; HR 0.30; 95% CI, 0.23 to 0.41; p<0.001).
EGFR-TKI therapy. Osimertinib The objective response rate was significantly better
with osimertinib (71%; 95% CI, 65 to 76) than with
Comparison:
platinum therapy plus pemetrexed (31%; 95% CI, 24
Pemetrexed to 40) (odds ratio for objective response, 5.39; 95% CI,
plus either carboplatin 3.47 to 8.48; p<0.001).
or cisplatin Second-line systemic anticancer therapy (SACT) with single agent drugs should be
considered. The choice of agent to be used should be mad

8. (Intervention, score 11) The Guideline Development Group highlighted this as a rapidly evolving area of research. with cytotoxic chemotherapy (used alone or in combination) and best supportive care. The study found an increased tumour response rate and prolonged progression-free survival compared to cytotoxic
chemotherapy.
Intervention Control Relative effect (95% CI)
Overall Survival PFS
Erlotinib vs. Cytotoxic chemotherapy HR 0.95 (0.75 to 1.22) HR 0.30 (0.24 to 0.38)
Gefitinib vs. Paclitaxel + carboplatin HR 0.95 (0.77 to 1.18) HR 0.39 (0.32 to 0.48)
Afatinib vs. Cytotoxic chemotherapy HR 0.93 (0.74 to 1.17) HR 0.42 (0.34 to 0

9. (Treatment, score 11) 0) with erlotinib and 5.5 months (4.4–7.1) with chemotherapy (HR 0.96, 95% CI 0.78–1.19; log-rank p=0.73). Median PFS in the erlotinib group was 6.3 weeks (95% CI 6.1–6.9) versus 8.6 weeks (7.1–12.1) in the chemotherapy group. There was no statistically significant difference in PFS between the two treatment groups (HR 1.19, 95% CI 0.97–1.46; p=0.089).
Row 10: |Intervention:|
Row 11: |Erlotinib|
Row 12: |Comparison:|
Row 13: |Chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators’ discretion)|
Row 14: Patient population:|Study/Author:|Results:
Row 15: Patients with stage

10. (Therapy, score 11) ng
chemotherapy alone to chemotherapy and thoracic RT totalling 2,140 patients, of which 433 were
excluded as they had extensive disease. 1,862 of the 2,103 patients who could be evaluated died; the
median follow-up of the surviving patients was 43 months. The relative risk of death in the combined
therapy group compared to the chemotherapy group was 0.86 (95% CI 0.78-0.94; p=0.001). There was
a 5.4% benefit in terms of overall survival at three years for the combined therapy group. The authors
concluded that thoracic RT moderately improves survival in patients with limited SCLC who are treated
with

## Comparator

1. (Control, score 7) control, or improved cost effectiveness compared with standard care alone (no involvement from specia
palliative care)?
Population: Patients with cancer (or specifically, lung cancer)
Intervention: Specialist Palliative care services
Comparison: Usual care (without palliative care)
Outcome: Symptom control, quality of life, cost-effectiveness, prognosis
Clinical question 2.8.2
Who should comprise the palliative care multidisciplinary team?
Population: Patients with cancer (or specifically, lung cancer)
Intervention: Multidisciplinary team care
Comparison: Usual care
Outcome: Symptom control, quality

2. (Usual care, score 6) |Symptom control, quality of life, cost-effectiveness, prognosis
Row 6: Clinical question 2.8.2 Who should comprise the palliative care multidisciplinary team?|
Row 7: Population:|Patients with cancer (or specifically, lung cancer)
Row 8: Intervention:|Multidisciplinary team care
Row 9: Comparison:|Usual care
Row 10: Outcome:|Symptom control, quality of life, cost-effectiveness, prognosis Row 1: Clinical question 2.8.1 Does the involvement of specialist palliative care result in better quality of life for patient or family, sym control, or improved cost effectiveness compared with standard care alone (n

3. (Control, score 5) adiation, no thoracic radio
Outcome: Survival, progression-free survival, response rate
| A National
the role of radio
C
py
otherapy
Clinic
other
cal Guideline
rapy Clinical question 2.8.1
Does the involvement of specialist palliative care result in better quality of life for patient or family, sym
control, or improved cost effectiveness compared with standard care alone (no involvement from specia
palliative care)?
Population: Patients with cancer (or specifically, lung cancer)
Intervention: Specialist Palliative care services
Comparison: Usual care (without palliative care)
Outcome: Symptom control

4. (Control, score 5) : Symptom control, quality of life, cost-effectiveness, prognosis
Clinical question 2.8.2
Who should comprise the palliative care multidisciplinary team?
Population: Patients with cancer (or specifically, lung cancer)
Intervention: Multidisciplinary team care
Comparison: Usual care
Outcome: Symptom control, quality of life, cost-effectiveness, prognosis
mptom
alist
122 | Diagnosis, staging and treatment of | A Natio
Appendix 3: Summary of the tools to assist in the impleme
this National Clinical Guideline
NCCP. National Clinical Guidelines for Cancer – Methodology Manual.
National Cancer Control Prog

5. (Control, score 5) views of RCTs, or RCTs with a very low risk of bias.
1+ Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias.
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias.
2++ High quality systematic reviews of case control or cohort studies.
High quality case control or cohort studies with a very low risk of confounding or bias and a high
probability that the relationship is causal.
2+ Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate
probability that the relationship is causal.
2- Case control or cohort studies

6. (Control, score 5) alyses, systematic reviews, or RCTs with a high risk of bias.
2++ High quality systematic reviews of case control or cohort studies.
High quality case control or cohort studies with a very low risk of confounding or bias and a high
probability that the relationship is causal.
2+ Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate
probability that the relationship is causal.
2- Case control or cohort studies with a high risk of confounding or bias and a significant risk that the
relationship is not causal.
3 Non-analytic studies (e.g. case reports, case

7. (Control, score 5) veness compared with standard care alone (no involvement from specialist palliative care)?|
Row 2: Population:|Patients with cancer (or specifically, lung cancer)
Row 3: Intervention:|Specialist Palliative care services
Row 4: Comparison:|Usual care (without palliative care)
Row 5: Outcome:|Symptom control, quality of life, cost-effectiveness, prognosis
Row 6: Clinical question 2.8.2 Who should comprise the palliative care multidisciplinary team?|
Row 7: Population:|Patients with cancer (or specifically, lung cancer)
Row 8: Intervention:|Multidisciplinary team care
Row 9: Comparison:|Usual care
Row 1

8. (Control, score 5) ost-effectiveness, prognosis
Row 6: Clinical question 2.8.2 Who should comprise the palliative care multidisciplinary team?|
Row 7: Population:|Patients with cancer (or specifically, lung cancer)
Row 8: Intervention:|Multidisciplinary team care
Row 9: Comparison:|Usual care
Row 10: Outcome:|Symptom control, quality of life, cost-effectiveness, prognosis Row 1: Clinical question 2.8.1 Does the involvement of specialist palliative care result in better quality of life for patient or family, sym control, or improved cost effectiveness compared with standard care alone (no involvement from specia palliat

9. (Control, score 5) w 8: Intervention:|Multidisciplinary team care
Row 9: Comparison:|Usual care
Row 10: Outcome:|Symptom control, quality of life, cost-effectiveness, prognosis Row 1: Clinical question 2.8.1 Does the involvement of specialist palliative care result in better quality of life for patient or family, sym control, or improved cost effectiveness compared with standard care alone (no involvement from specia palliative care)?
Row 2: Population:
Row 3: Intervention:
Row 4: Comparison:
Row 5: Outcome:
Row 6: Clinical question 2.8.2 Who should comprise the palliative care multidisciplinary team?
Row 7: Population

10. (Control, score 5) s with a very low risk of bias.
Row 2: 1+|Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias.
Row 3: 1-|Meta-analyses, systematic reviews, or RCTs with a high risk of bias.
Row 4: 2++|High quality systematic reviews of case control or cohort studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal.
Row 5: 2+|Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal.
Row 6: 2-|Case control or

## Outcome

1. (Effect, score 14) let regimen, but
not for 1-year survival (OR, 1.01; 95% CI, 0.85-1.21; p=0.88). The median survival ratio was 1.00 (95% CI,
0.94-1.06; p=0.97). The study concluded that in patients with advanced NSCLC a second drug improved
tumour response and survival rate and that adding a third drug had a weaker effect on tumour response
and no effect on survival.
A non inferiority, phase III, randomised study (Scagliotti et al., 2008) compared the overall survival of
cisplatin/pemetrexed with cisplatin/gemcitabine in chemotherapy-naive patients with advanced NSCLC.
Overall survival for patients randomly assigned

2. (Outcome, score 13) ectiveness of stereotactic radiotherapy, standard radical radiotherapy and radiofrequency ablation?|
Row 2: Population:|In patients with Stage I, II who are unfit for surgery
Row 3: Intervention:|Stereotactic RT, standard radical radiotherapy, and radiofrequency ablation
Row 4: Comparison:|-
Row 5: Outcome:|Median survival, two year survival, five year survival, progression-free survival, overall survival, response rate, declining lung function, pneumonitis, pulmonary fibrosis, quality of life
Row 6: Clinical question 2.7.2 In patients with stage I-III NSCLC undergoing radical external beam radiation

3. (Effect, score 13) urvival (OR, 1.01; 95% CI, 0.85-1.21; p=0.88). The median survival ratio was 1.00 (95% CI,
0.94-1.06; p=0.97). The study concluded that in patients with advanced NSCLC a second drug improved
tumour response and survival rate and that adding a third drug had a weaker effect on tumour response
and no effect on survival.
A non inferiority, phase III, randomised study (Scagliotti et al., 2008) compared the overall survival of
cisplatin/pemetrexed with cisplatin/gemcitabine in chemotherapy-naive patients with advanced NSCLC.
Overall survival for patients randomly assigned to cisplatin/pemetrexed was noni

4. (Outcome, score 12) disease (T1-T2 N0 M0) wh
for surgery, what is the effectiveness of stereotactic radiotherapy, standard radical radio
radiofrequency ablation?
Population: In patients with Stage I, II who are unfit for surgery
Intervention: Stereotactic RT, standard radical radiotherapy, and radiofrequ
Comparison: -
Outcome: Median survival, two year survival, five year survival, progress
overall survival, response rate, declining lung function, pneum
fibrosis, quality of life
Clinical question 2.7.2
In patients with stage I-III NSCLC undergoing radical external beam radiation therapy wh
effectiveness of the following

5. (Result, score 11) SBRT over 3D-CRT was $6,000/quality- adjusted life-year, and the incremental cost-effectiveness ratio for SBRT over RFA was $14,100/quality- adjusted life-year. One- way sensitivity analysis showed that the results were robust across a range of tumour sizes, patient utility values, and costs. This result was confirmed with probabilistic sensitivity analyses that varied local control rates and utilities. Row 1: |Intervention Row 1: n|Ana Row 1: |Clinical & QALY Outcomes|Costs
Row 2: |In the surgical group operative mortality was 4 (7%) of 57. Median survival was 4.2 years, and 4-year survival was 51

6. (Outcome, score 9) ention: Surgical resection
Comparison: -
Outcome: Survival (one year, three year, five year)
Clinical question 2.5.10
Should surgical resection be considered as part of the multimodality treat
(N2) NSCLC?
Population: Patients with stage IIIa (N2) NSCLC
Intervention: Surgical resection
Comparison: -
Outcome: Survival
Clinical question 2.5.11
In patients with small-cell lung cancer (SCLC) what is the role of surgery?
Population: Patients with SCLC
Intervention: Surgery
Comparison: -
Outcome: Survival
| A National Clinical Guideline
al resection?
tion
on-free survival, overall survival,
hat is the best

7. (Effect, score 9) e control group (HR 0.27; p<0.001). PCI was associated with an
increase in median overall survival from 5.4 to 6.7 months after randomisation. The 1-year survival rate
was 27.1% in the PCI group and 13.3% in the control group (p=0.003). PCI had side effects but did not
have a clinically significant effect on global health status. The largest mean difference between the two
arms was observed in fatigue and hair loss, which were greater in those who received PCI (Slotman et
al., 2009). PCI reduced the incidence of symptomatic brain metastases and prolonged overall survival in
patients with extensive-s

8. (Outcome, score 8) parison: -
Outcome: Two year survival, five year survival, peri-operative mortality
Clinical question 2.5.6:
In patients with NSCLC what is the optimum surgical approach for?
a) Multifocal tumours
b) Synchronous tumours
Population: NSCLC patients with multifocal or synchronous tumours Comparison: -
Outcome: Two year survival, five year survival, progression-free survival, overall sur
on eff
tomy)
rvival,
rgery (
rvival,
gery
rvival
ffect
(VATS)
116 | Diagnosis, staging and treatment of
Clinical question 2.5.7
In patients with NSCLC, what is the optimal lymph node strategy at surgica
Population: Patie

9. (Outcome, score 8) utcome:|Two year survival, five year survival, progression-free survival, overall survival Row 1: Clinical queation 2.5.1 In patients with stage I & II non-small cell lung cancer (NSCLC) how does the extent of lung resectio outcomes?
Row 2: Population:
Row 3: Intervention:
Row 4: Comparison:
Row 5: Outcome:
Row 6: Clinical question 2.5.2 In patients with clinical stage I NSCLC undergoing lobectomy, how does video-assisted thoracic sur compare to thoracotomy?
Row 7: Population:
Row 8: Intervention:
Row 9: Comparison:
Row 10: Outcome:
Row 11: Clinical question 2.5.3 Which pulmonary function tests shoul

10. (Effect, score 8) trials of postoperative
radiotherapy versus surgery alone. Data on 2128 patients from nine randomised trials (published and
unpublished) were analysed by intention to treat. Median follow-up was 3.9 years (2.3–9.8 for individual
trials) for surviving patients. The results show a significant adverse effect of postoperative radiotherapy
on survival (HR 1.21 [95% CI 1.08–1.34]). Subgroup analyses suggest that this adverse effect was greatest
for patients with stage I/II, N0–N1 disease, whereas for those with stage III, N2 disease there was no clear
evidence of an adverse effect. The authors concluded t

